Identification of patients affected by mitral valve prolapse with severe regurgitation : A multivariable regression model by P. Songia et al.
Research Article
Identification of Patients Affected by Mitral Valve Prolapse with
Severe Regurgitation: A Multivariable Regression Model
Paola Songia,1,2 Benedetta Porro,1 Mattia Chiesa,1 Veronika Myasoedova,1
Francesco Alamanni,1,3 Elena Tremoli,1 and Paolo Poggio1
1Centro Cardiologico Monzino IRCCS, Milan, Italy
2Dipartimento di Scienze Farmacologiche e Biomolecolari, Universita` degli Studi di Milano, Milan, Italy
3Dipartimento di Scienze Cliniche e di Comunita`, Universita` degli Studi di Milano, Milan, Italy
Correspondence should be addressed to Paolo Poggio; paolo.poggio@ccfm.it
Received 8 September 2016; Revised 30 December 2016; Accepted 11 January 2017; Published 2 February 2017
Academic Editor: Cecilia Zazueta
Copyright © 2017 Paola Songia et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background. Mitral valve prolapse (MVP) is the most common cause of severe mitral regurgitation. Besides echocardiography, up
to now there are no reliable biomarkers available for the identification of this pathology. We aim to generate a predictive model,
based on circulating biomarkers, able to identify MVP patients with the highest accuracy. Methods. We analysed 43 patients who
underwent mitral valve repair due toMVP and compared to 29matched controls.We assessed the oxidative stress status measuring
the oxidized and the reduced form of glutathione by liquid chromatography-tandem mass spectrometry method. Osteoprotegerin
(OPG) plasma levels were measured by an enzyme-linked immunosorbent assay. The combination of these biochemical variables
was used to implement several logistic regressionmodels.Results. Oxidative stress levels andOPG concentrations were significantly
higher in patients compared to control subjects (0.116 ± 0.007 versus 0.053 ± 0.013 and 1748 ± 100.2 versus 1109 ± 45.3 pg/mL,
respectively; 𝑝 < 0.0001). The best regression model was able to correctly classify 62 samples out of 72 with accuracy in terms of
area under the curve of 0.92. Conclusions. To the best of our knowledge, this is the first study to show a strong association between
OPG and oxidative stress status in patients affected by MVP with severe regurgitation.
1. Introduction
Myxomatous mitral valve prolapse (MVP) is the most com-
mon indication for mitral valve surgery due to severe mitral
regurgitation (MR).The prevalence ofMVP is estimated at 2-
3%with approximately 144million people affectedworldwide
[1]. Echocardiographically, MVP is defined as a single or
bileaflet prolapse, at least 2mm beyond the long-axis annular
plane, while the assessment of valve regurgitation takes into
account the effective regurgitant orifice area (EROA) [2].
Interestingly, the pathology is equally distributed between
men and women [3] and patients with prolapse have signif-
icantly lower body-mass index (BMI) and waist-to-hip ratio
than those without prolapse [1].
Despite the pathology was first described in the late 1800s
[3], no major risk factor has been identified yet [4] and the
triggering mechanisms of MVP are not fully understood. In
this context, a very recent study byDeroyer et al. [5] showed a
negative association between severity ofMRandhigh-density
lipoproteins (HDL) levels. Interestingly, HDL concentrations
and levels of Apo-A1, the major protein component of
HDL, which participates in the reverse cholesterol transport,
decreased according to the severity of MR. In addition, MVP
patients showed an alteration in the antioxidant defence
systems and an increase in lipid peroxidation markers [6].
Given the background, we investigated Osteoprotegerin
(OPG), a well-known protein linked to oxidative stress
status [7] and to endothelial mesenchymal transition on
endothelial cells isolated from MVP patients [8]. OPG is a
secretory glycoprotein of the tumour necrosis factor receptor
superfamily involved in calcification, apoptosis, proliferation,
and migration processes [9]. It possesses high affinity to
receptor activator of nuclear factor-kb (RANKL), to tumour
necrosis factor-related apoptosis-inducing ligand (TRAIL),
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Table 1: Patient demographics.
Control (𝑁 = 29) MVP (𝑁 = 43) 𝑝 value
Variable
Age (years) 57.3 [53.2, 61.4] 60.1 [56.8, 63.5] 0.291
Sex (male) 19 (65.5%) 29 (67.4%) 0.865
Diabetes 3 (10.3%) 3 (7.0%) 0.685
Hypertension 14 (48.3%) 16 (37.2%) 0.660
Hypercholesterolemia 14 (48.3%) 25 (58.1%) 0.688
Smokers 6 (20.7%) 5 (11.6%) 0.514
BMI 27.4 ± 0.76 24.8 ± 0.43 0.005
Total cholesterol (mg/dL) 216.1 ± 7.4 215.2 ± 6.6 0.973
Triglycerides (mg/dL) 111.2 ± 9.0 110.3 ± 6.7 0.690
HDL (mg/dL) 55.8 ± 3.2 51.3 ± 1.9 0.249
LDL (mg/dL) 138.0 ± 7.1 132.4 ± 6.5 0.658
NYHA class 0.001
I 29 (100%) 19 (44.2%)
II — 17 (39.5%)
III — 7 (16.3)
IV — —
Drug therapies
Antiplatelets (%) 1 (3%) 2 (5%) 1.00
Angiotensin receptor blockers (%) 4 (14%) 3 (7%) 0.429
Converting enzyme inhibitors (%) 5 (17%) 14 (32%) 0.295
Calcium channel blockers (%) 3 (10%) 3 (7%) 0.679
Beta-blockers (%) 1 (3%) 16 (37%) 0.007
Nitrates (%) 0 (0%) 1 (2%) 1.00
Statins (%) 6 (21%) 6 (14%) 0.527
BMI: body mass index; HDL: high-density lipoprotein; LDL: low-density lipoprotein; NYHA: New York Heart Association. [minimum, maximum];
(percentage); mean ± standard error.
and to syndecan family receptors (SDC). This molecule has
been associated with cardiometabolic disorders [9], as well
as increased cardiovascular and overall mortality [10, 11]. In
addition, it has been shown that transforming growth factor
beta (TGF-𝛽), a well-known player in myxomatous MVP
pathogenesis [12], increases oxidative stress status [13] as well
as OPG production and secretion directly stimulating OPG
promoter activity [14].
In this study, we aim to generate a predictive model able
to identify MVP patients with the highest accuracy with the
combination of biochemical parameters easily quantifiable.
2. Patients and Methods
2.1. Patient Demographics. This observational study was
approved by the Institutional ReviewBoard and by the Ethical
Committee of CentroCardiologicoMonzino (CCM), IRCCS.
The investigation conformed to the principles outlined in the
Declaration of Helsinki (1964).
A total of 51 consecutive patients that underwent mitral
valve repair, at CCM, due to MVP were enrolled. Based
on exclusion criteria (presence of bicuspid aortic valve,
premature menopause, and/or osteoporosis, prior aortic or
mitral valve surgery, rheumatic heart disease, endocarditis,
active malignancy, chronic liver failure, calcium regulation
disorders, and chronic or acute inflammatory states), we
selected and analysed 43 patients matched by age, sex,
diabetes, hypertension, hypercholesterolemia, and smoking
habits with 29 control subjects from those attending the clinic
for global control of cardiovascular risk at CCM. The demo-
graphic and clinical features of the two study groups are listed
in Table 1. The subjects were assessed with detailed medical
history, physical examination, and echocardiography. In all
patients, blood collection was performed before coronary
angiography and surgery, with the exception of controls,
which underwent samples collection at a scheduled visit.
2.2. Blood Sampling and Biochemical Measurements
Whole Blood. Peripheral blood sample was drawn from
patients and controls while fasting into tubes containing
EDTA (9.3mM; Vacutainer Systems, Becton Dickinson,
Franklin Lakes,NJ,USA) kept on ice and immediately precip-
itatedwith 10% trichloroacetic acid (Sigma-Aldrich, St. Louis,
MO, USA) in 1mM EDTA solution. After centrifugation at
10,000𝑔 for 10min at 4∘C, the supernatant was stored at
−80∘C until analysis.
Plasma. EDTA anticoagulated blood was centrifuged at
3,000𝑔 for 10min at 4∘C within 30min after being drawn.
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Plasma was separated and aliquots were stored at −80∘C until
analysis.
2.3. Oxidative Stress Measurement. For oxidative stress eval-
uation whole blood concentrations of the oxidized (GSSG)
and reduced (GSH) form of glutathione, whose ratio
(GSSG/GSH) is a well-recognized index, were assessed by a
previously developed and validated LC-MS/MS method [15].
2.4. Osteoprotegerin Evaluation. Plasma levels of soluble
OPGweremeasured with an enzyme-linked immunosorbent
assay (ELISA) kit (DuoSet, R&D) following manufacturer
instructions. The standard of this particular kit is similar to
full-length OPG, making this ELISA kit more representative
of circulating OPG molecule [9].
2.5. Statistical Analysis. Continuous variables are summa-
rized as mean ± standard error, except for age, which is rep-
resented as mean [minimum, maximum], while categorical
variables are summarized as frequency and percentage.
For data analysis, Mann–Whitney test has been per-
formed between MVP and control classes on continuous
variables, while Fisher’s exact test has been performed on
discrete ones.
Finally, taking into account OPG measurement and
GSSG/GSH ratio, we have implemented several logistic
regression procedures in order to identify a classification rule,
able to predict outcomes with the highest accuracy.
The logistic model is
𝑝 (𝑌𝑖 = “MVP”) =
1
1 + 𝑒−(𝛽0+𝛽1𝑥1+𝛽2𝑥2)
, (1)
where 𝑝 is probability to have MVP, 𝑥1 is OPGmeasurement
(in pg/mL), and 𝑥2 is GSSG/GSH ratio.
A receiver operating characteristic (ROC) curve has been
plotted for eachmodel andperformances have been evaluated
by comparing areas under the ROC Curve (AUC).
3. Results
3.1. Patient Characteristics. In this study we analysed 43
patients and 29 controls matched by age, sex, diabetes, hyper-
tension, hypercholesterolemia, and smoking habits. The two
groups were comparable for all the clinical and demographic
features considered, except for BMI, which was significantly
lower in MVP patients than in controls (𝑝 = 0.005), and as
expected,NewYorkHeart Association (NYHA) class that was
significantly higher in MVP patients (𝑝 < 0.001, Table 1).
Drug therapies were not significantly different betweenMVP
and controls, apart from beta-blockers, mostly taken by
patients. However, up to now, no data are available about
any influence of this drug class on oxidative stress levels. In
Table 2 the qualitative and quantitative echocardiographic
characteristics of mitral valves are reported. As expected the
peak E velocity and the ratio between peak E and peak A
velocity (E/A ratio) were significantly different between the
two groups (𝑝 < 0.001).
Table 2: Echocardiography evaluation.
Echocardiography
parameters Control (𝑁 = 29) MVP (𝑁 = 43) 𝑝 value
LVEF (%) 65.9 ± 1.6 63 ± 1.6 0.416
Peak 𝐸 velocity (cm/s) 72.8 ± 3.8 103 ± 4.2 <0.001
Deceleration 𝐸 (ms) 229 ± 13.4 199 ± 7.7 0.094
Peak 𝐴 velocity (cm/s) 79.1 ± 4.8 68.9 ± 2.8 0.111
𝐸/𝐴 ratio 0.96 ± 0.07 1.6 ± 0.1 <0.001
EROA (cm2) — 0.6 ± 0.04
LVEF: left ventricular ejection fraction; EROA: effective regurgitant orifice
area. Mean ± standard error.
3.2. Osteoprotegerin Levels and Oxidative Stress Status. The
assessment of OPG levels revealed that this protein was
significantly higher in MVP patients when compared to
controls (1748±100.2 versus 1109±45.3 pg/mL, respectively;
𝑝 < 0.0001, Figure 1(a)). Since it has already been shown that
OPG concentration increases with age [9], we implemented
an adjustedmodel for this variable and the difference between
the groups maintains its significance (𝑝 < 0.0001). In
addition, we adjusted for NYHA class as well as BMI and
the difference in OPG levels remained significant between
the two groups (𝑝 < 0.01). Finally, we confirmed that
the oxidative stress status, represented by GSSG/GSH ratio,
was higher in MVP patients compared to control subjects
(0.116 ± 0.007 versus 0.053 ± 0.013, respectively; 𝑝 < 0.0001,
Figure 1(b)) and remained significant even after NYHA class
and BMI adjustment (𝑝 < 0.01). Notice that no correlation
has been found between NYHA class and OPG levels or
GSSG/GSH ratio.
3.3. Binary Logistic Regression Model. To assess if OPG
or GSSG/GSH ratio could be used as potential circulating
markers of MVP, we implemented a step-wise binary logistic
regression model. To further improve the specificity and
sensibility, we took OPG and GSSG/GSH ratio alone and
then together. We also evaluated their possible interaction;
however, it was not statistically significant (𝑝 = 0.243) and
therefore we did not include it in the regression model. The
regression parameters obtained from estimation procedure
were 𝛽0 = −7.590, 𝛽1 = 0.005, and 𝛽2 = 24.493. The logistic
model implemented is described in Section 2.5. This model
was able to correctly classify 62 samples out of 72 (Figure 2).
In addition, the logistic regressionmodel pointed out an odds
ratio of 38.5 (95% CI: 9.9–150.6; 𝑝 < 0.0001) to haveMVP for
subjects with 𝑝(𝑌𝑖 = “MVP”) > 0.5.
3.4. Combination of Osteoprotegerin and Oxidative Stress
as Potential Circulating Marker of MVP. Receiver operator
characteristic curve (ROC) was performed to determine if
OPG or GSSG/GSH ratio alone or together could be used
to identify MVP patients. As shown in Figure 3, OPG and
GSSG/GSH ratio had an area under ROC curve (AUC) of
0.83 and 0.79, respectively (𝑝 < 0.0001). However, if we
considered OPG combined with GSSG/GSH we observed
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Figure 1: Osteoprotegerin and oxidative stress levels. (a) Osteoprotegerin (OPG) enzyme-linked immunosorbent assay (ELISA) on plasma
samples from control subjects (CTRL) and mitral valve prolapse (MVP) patients. (b) Ratio between oxidized (GSSG) and reduced (GSH)
form of glutathione as oxidative stress status index.
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Figure 2: Binary logistic regression model. Graph representing the
prediction of the best binary logistic regression model.
accuracy in terms of AUC of 0.92 with 95%CI: 0.86–0.98 and
𝑝 < 0.0001 (red thick line; Figure 3).
4. Discussion
Myxomatous mitral valve prolapse (MVP) with severe regur-
gitation (MR) is the most common cause for mitral valve
surgery. The MVP diagnosis is some of the most challenging
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Figure 3: Osteoprotegerin combinedwith oxidative stress, as poten-
tial circulating marker of MVP. Receiver operating characteristic
(ROC) curves and area under the curve (AUC) of Osteoprote-
gerin (OPG), ratio between oxidized (GSSG) and reduced (GSH)
form of glutathione (GSSG/GSH) and their combination (OPG +
GSSG/GSH). (Control subjects 𝑛 = 29, Mitral Valve Prolapse
patients 𝑛 = 43; 𝑝 < 0.0001).
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aspects in clinical cardiology and, up to now, echocardio-
graphy is the only clinical reliable tool. No biomarkers are
available for this pathology and, to the best of our knowledge,
only a comparative proteomic study on plasma samples
from 24 pooled MVP patients with moderate to severe MR
revealed reduced levels of haptoglobin, platelet basic protein,
and complement component C4b in the MVP/MR patients
as compared to the 24 pooled matched control cases [16].
However, the clinical applicability is unclear, in part because
most of the identified biomarkers had low AUC. In addition,
Thalji et al. [12] and Sainger et al. [17] identified novel
players that could be involved in myxomatous mitral valve
degeneration and their data offer novel insights into the
pathogenesis of MVP but no circulating biomarkers have
been evaluated.
Results of the present work show that circulating OPG
and oxidative stress status are positively associated with
severe MR due to MVP. Based on these premises, we devel-
oped a multivariable logistic regression model with OPG and
GSSG/GSH levels.Thismodel is able to correctly identify 86%
of MVP patients and 86% of control subjects.
Since all patients, in the MVP group, were the ones
who underwent surgery due to symptoms, we evaluated and
excluded that left ventricular ejection fraction (LVEF) and
heart failure (NYHA classes) were the causes that increased
OPG plasma levels and oxidative stress status. Therefore,
our data supports that severe MR caused by myxomatous
MVPcould be identify through amultivariable binary logistic
regression model.
The analyses of OPG as well as oxidative stress alone are
not disease specific; indeed OPG has already been linked to
coronary artery syndromes [18], aortic valve stenosis [19],
myocardial infarction [20], and cardiovascular postoperative
outcome [21].However, the combination of these biochemical
parameters allowed us to identify these patients with high
accuracy.
Recently, we showed that OPG was involved in mitral
valve endothelial to mesenchymal transition and plasma
OPG levels permitted to identify MVP patients with an AUC
of 0.92 [8]. However, all the selected MVP patients had only
posterior MVP. It is known that two-thirds of MVP patients
present the posterior prolapse, while the remaining third
show anterior or bileaflet prolapse [22, 23]. Considering this,
to obtain a model able to discriminate MVP from healthy
subjects, in primary screening, wemust use a populationwith
not only posterior but also anterior and bileaflet prolapse.
Thus, in the present study we enrolled 43 MVP patients: 28
with posterior MVP (65%) and 15 with anterior or bileaflet
MVP (35%). In this population, OPG had an AUC of 0.83
that was brought back to 0.92 when OPG was combined with
GSSG/GSH ratio; meaning that OPG alone is not sufficient to
discriminate with high accuracy the MVP mixed population
(posterior, anterior, and bileaflet) from healthy subjects.
The present study has some limitations: first, the exiguous
number of patients enrolled and the lack of strong disease-
specificity ofOPG and oxidative stress withMVP. In addition,
in our cohorts we had only two cases with mitral annulus
calcification (MAC). Since OPG is involved in many cellular
processes, in particular calcification, further studies need to
address also the possible implication of thismolecule not only
in patients with MAC but also in those who have mitral valve
stenosis. Lastly, patients with severe regurgitation compose
the MVP cohort and further studies are needed to evaluate
if this model is able to discriminate mild or moderate mitral
valve regurgitation in the presence or absence of prolapse.
5. Conclusion
In conclusion, considering the prevalence of this disease (over
6% ≥65 years old [1]), the aging population, and the price
of the echocardiographic evaluation, the health system costs
may rise if no pharmacological treatment or cheaper diagno-
sis tools will be identified. In particular, circulatingmolecular
signatures could be used in primary screening to identify
possible MVP patients and then a confirmatory echocardio-
graphy could be performed only in these subjects. Thus, the
study of new circulating markers and the combination of
already known ones involved in MVP progression could lead
to novel insights and possibly new therapeutic targets. To
the best of our knowledge, this is the first study to show a
strong association between OPG and oxidative stress status.
In addition, thesemolecules could bemeasured in the clinical
setting by the implementation and validation of diagnostic
enzyme-linked immunosorbent assay (ELISA) for OPG and
colorimetric assay for GSH andGSSG. Finally, since it is quite
hard to believe that one single protein could discriminate two
populations with high specificity and sensitivity, we believe
that this approach could improve the identification of several
signatures not only in mitral valve disease. However, the
mechanisms explaining these correlations are still unclear;
further molecular studies along with clinical validations will
be necessary to confirm our findings.
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